Recruiting
Phase 2

Teclistamab & Daratumumab

Sponsor:

Suzanne Lentzsch, MD

Code:

NCT07110844

Conditions

Amyloid Light-chain Amyloidosis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Teclistamab

Daratumumab and Hyaluronidase-fihj

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-23. This information was provided to ClinicalTrials.gov by Suzanne Lentzsch, MD on 2025-11-19.